insitro

#AI is shaking up drug discovery ?? and next week at #HLTH2024 our very own Mary Rozenman joins the “Algorithms & Assays” panel chaired by Christina Jenkins, MD of Convergent Ventures. Mary will explain how insitro applies #machinelearning to reinvent drug discovery and improve probability of success, starting with our differentiated therapeutic hypotheses that help us identify both targets and potential patient populations. ?? We also apply AI to optimizing molecular design and identifying biomarkers for clinical studies.? She will also share more about our latest collaboration with Eli Lilly and Company and our unique partnership model. Hope you can hear Mary and other experts break down the data challenges, biological complexity, and erroneous outputs with us on October 22nd at 2:30 p.m. on the Gallery Stage. ?? See you in Las Vegas!

Thrilled to see our insitrocytes making waves at #SfN24! ?? Cynthia Hao will present some of our work on #ALS, sharing insights from insitro’s large-scale pooled optical screen TDP-43-regulated splicing modifiers. ?? Also participating are Jasmine Roberts and Harris Nami, M.A.Sc., showcasing posters on how we’re blending cutting-edge tools like MEA and QPI to fuel discovery. Thanks, Max Salick, for sharing the exciting work our team pushed to fruition. Discover more below. ??

insitro is proud to be working with Eli Lilly and Company, as we move closer towards IND-enabling studies for our first wholly-owned pipeline programs in metabolic disease. This is a new partnership paradigm that brings together #machinelearning (ML), multimodal data and outstanding drug discovery capabilities. This model, encompassing three agreements, turns the traditional pharma-biotech collaboration model on its head: - The three targets were all derived from insitro’s proprietary, ML-driven discovery platform. - In the first two programs, insitro will combine Lilly’s proprietary GalNAc technology for liver-targeted delivery with two proprietary siRNA molecules discovered and developed by insitro. - In the third program, Lilly and insitro will collaborate to design an antibody-based therapeutic against a third target, which insitro will develop.? - This is a win-win structure with insitro retaining full global rights to its programs and Lilly eligible to receive potential milestones and royalties. We can accelerate insitro’s #ML-driven, genetically-defined therapeutic hypotheses to the clinic by uniting insitro's machine learning platforms with Lilly’s expertise in cutting-edge biologics design. To learn more, click to watch a video with our CFO/CBO Mary Rozenman and click here to read the press release: https://lnkd.in/ejPmKPdZ

Want to make a difference for patients? Want to work in a collaborative, “bilingual” culture where computational and biological scientists learn each other’s language? Then join us because insitro is reimagining #drugdiscovery and development through machine learning. We're hiring talented scientists and engineers to join us in creating transformative therapies. Here are a few opportunities to make an impact: ?? Data Scientist IV/V, Computational Chemistry: Apply cutting-edge #ML and physics-based models to accelerate the development of clinical molecules. https://lnkd.in/emg7dD2Z ?? Director/Senior Director, Neurodegeneration: Lead cross-functional teams in the development of novel therapeutic strategies for neurodegenerative diseases, translating genetic insights into actionable therapeutic targets. https://lnkd.in/epDX8QiB ???? Senior Director/VP, Translational Medicine and Diagnostics: Oversee and drive clinical programs in neurology, oncology, and metabolic diseases, leveraging #AI/ML to optimize trial design and improve patient outcomes. https://lnkd.in/eAKtQf5K ?? Computational Microscopy Engineer IV: Design and develop advanced imaging pipelines, collaborating with discovery teams to identify and validate new therapeutic targets through innovative microscopy methods. https://lnkd.in/e2vKKRV2 Join our team of scientists, engineers, and drug developers committed to rigorous science and collaboration. ???Explore these and other opportunities at insitro.com/join-us. #biotech #lifesciences

Meet Jana Mitchell, PhD, a principal scientist focusing on ALS research at insitro! She recently showcased how her team is using ML in #ALS, focusing on phenotypic discovery, at ISSCR 2024. They are building innovative models, constructed using iPSC-derived motor neurons, in order to provide novel insights into ALS pathology and potential therapeutic targets. Jana’s takeaways from ISSCR: ?? A reminder of why I got into the life sciences ?? Deep dive sessions were her favorite parts ?? I can see how the whole field is advancing Jana and her colleagues are harnessing the power of #ML to identify subtle disease patterns that may elude even the most trained human eye. By merging insitro's core technologies — automated iPSC-based cell differentiation and machine learning-driven target discovery — we can unlock new methods for examining human cell types, advancing drug discovery. For more on Jana, see her insitrocyte profile below.

How can #machinelearning help us find better medicines and reinvent #drugdiscovery? Join insitro CEO and founder Daphne Koller on Monday in Boston at Fierce Biotech’s #FierceBiotechSummit 2024 for the kick-off keynote. She will take you inside insitro, diving deep into what the #AI wave means for discovery including: ?? Why a “quiet” revolution in #biology is just as significant as the AI revolution ?? How high-quality data and AI are uncovering novel drug targets? ?? What we’re doing to find new therapies for the patients who can benefit most Catch the future of therapeutics discovery and development. Learn more and register: https://lnkd.in/gZiJ8nHE

insitro VP, Metabolic Disease David Lloyd is set to shine ? at the 8th Annual MASH Drug Development Summit in Boston!?He’ll be sharing his expert insights ???? on how #machinelearning is revolutionizing genetic target discovery and novel therapies for #MASH.

Check it out! Last week Christoph Klein, our director of software engineering, presented to a terrific 200+ crowd for Biocom California’s Converge Meet-Up event co-hosted by Bits in Bio and Nucleate. He joined speakers from InstaDeep, ThinkingNode Life Science, Inc., NVIDIA, EvolutionaryScale and Sphinx Bio. Thank you to all the organizers for putting on such a lovely event to network, compare notes, and find more opportunities to cross-pollinate. Christoph presented how insitro built and invested in “POSH” (Pooled Optical Screening in Human cells). He talked about all the ways our software teams worked closely with our wet lab scientists to build and scale this unique capability to perform genetic screening up to genome-wide scale.? ?? What is POSH? ?? It enables unbiased target discovery and is powered by #machinelearning ?? It combines high throughput gene editing with multimodal image-based phenotyping ??It investigates perturbations of cellular systems – at scale – to develop better therapeutic targets ?? It works across different disease areas and imaging modalities, making it a versatile discovery engine POSH helps us decode biology and find better starting points for new medicines.??? If you want to work on POSH or one of the other bleeding edge platform tools our team is inventing and/or building, check out our careers page. https://lnkd.in/eTueFdYN

What is Possible? Reinventing drug discovery. That is the topic Daphne Koller explores in depth with Reid Hoffman and Aria Finger on their signature Possible podcast. It starts with the ability to measure #biology at high fidelity and scale, across multiple modalities – a perfect opportunity for #machinelearning. That enables us to do more by “taking the data you get and creating from it the data that you don’t have,” as Daphne describes it - opening the door to new insights on disease that underpin new therapeutic interventions. Tune in to hear: ?? how we uncover new therapeutic hypotheses? ?? the distinction between personalized and personal medicine? ?? why exponential curves are deceptive ?? what her postdoc advisor Stuart Russell asked that made Daphne’s jaw drop? ??? a surprising book pick that helps Daphne stay optimistic Spoiler alert - it’s not in the life sciences, but about our shared long term future. “Not the End of the World: How We Can Be the First Generation to Build a Sustainable Planet.”??? Don’t miss this exciting conversation from the industry’s best. Listen below. ?

Drum roll… insitro joins Fast Company’s 2024 100 Best Workplaces for Innovators list! Proud to be #21 and to be home to leading minds in #drugdiscovery and #machinelearning to bring better medicines faster to the patients who can benefit most. We believe the solution to the toughest challenges in medicine lies at the intersection of machine learning and tremendous advances in biology. That’s why we foster bilingualism so life scientists and computational scientists as well as engineers and researchers can learn from each other and work side by side. No surprise: two of our core values are to “be bold” and “create together.” #FCBESTWORKPLACES recognizes this unique culture, where creativity thrives and collaboration is natural. Kudos to all the other innovators bringing people together to push the boundaries in their fields. Check out the list: https://lnkd.in/dJJEm8K4